Using breath tests to predict response to lung cancer immunotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the role of fractional exhaled nitric oxide (FeNO) as a prognostic marker for predicting the response to anti-PD-L1 immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC). Participants will undergo breath testing to measure FeNO levels before starting immunotherapy and again after the fourth treatment session. The study seeks to determine if FeNO levels can provide a more accurate prediction of treatment efficacy compared to current markers. By understanding the relationship between FeNO and treatment response, the study hopes to improve personalized treatment strategies for lung cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with metastatic NSCLC
* Patient not previously treated
* PD-L1 tumor expression \> 50%, to be treated with immunotherapy alone after validation by a multidisciplinary consultation meeting.
* Patients over 18 years of age
* Patient having given his/her non-opposition
* Patient who speaks and reads French

Exclusion Criteria:

* Patients previously treated for NSCLC
* Patient with oncogene addiction or a first-line targetable rearrangement
* Patient not suitable for immunotherapy alone
* Patient having received corticosteroid treatment in the 15 days prior to FeNO.
* Patient on inhaled corticosteroid at time of inclusion.
* Blood eosinophilia \> 500 /mm3
* Patient on 24-hour oxygen therapy
* Contraindication to immunotherapy
* Inability to perform FeNO measurement manoeuvres
* Pregnant, parturient or breast-feeding women
* Person under judicial protection (curatorship, guardianship)
* Person subject to limited judicial protection
* Adult unable to express their non-opposition
* Patient refusing to participate in the study

Where it's running

• Chu Dijon Bourgogne
  Dijon, France Recruiting

Study contacts

• Study coordinator: Marjolaine GEORGES
• Email: marjolaine.georges@chu-dijon.fr
• Phone: 03.80.29.37.72

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DS-3939a in solid tumors and non-small cell lung cancer

  This study tests DS-3939a, alone or with other anticancer drugs, in adults with solid tumors including locally advanced or metastatic NSCLC to see if it is safe and helps control the disease.

  Recruiting at 3 sites Phase 1/2 Daiichi Sankyo · Fayetteville, Arkansas and 75 other locations · NCT07739966

• Safety and activity of radioligand therapy with RTX-2358 plus immune therapy in FAP-positive metastatic NSCLC

  A small, early study tests whether giving a targeted radioligand to patients with FAP-positive metastatic NSCLC, combined with a PD-1 inhibitor, is safe and shows signs of activity.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07689643

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

• Firmonertinib versus standard EGFR drugs as first treatment for advanced NSCLC with EGFR PACC mutations

  This trial tests whether daily firmonertinib works better than standard EGFR drugs (osimertinib or afatinib) as the first treatment for people with advanced NSCLC that has EGFR PACC mutations.

  Recruiting at 141 sites Phase 3 ArriVent BioPharma, Inc. · Fullerton, California and 140 other locations · NCT07185997

• Ubamatamab with or without REGN7075 for adults with advanced or metastatic non-small cell lung cancer

  This trial will try ubamatamab alone and with REGN7075 in adults with advanced or metastatic non-small cell lung cancer to see if they control the cancer and will try sarilumab to manage immune-related side effects.

  Recruiting at 18 sites Phase 2 Regeneron Pharmaceuticals · Birmingham, Alabama and 17 other locations · NCT07154290

• MOv19-BBz CAR T cell treatment for FRa-positive lung cancer

  This trial will test whether a single intrapleural infusion of MOv19-BBz CAR T cells given after lymphodepleting chemotherapy is safe and can help control FRa-positive metastatic or recurrent non-small cell lung cancer with malignant pleural effusion.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07116057

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.